Fig. 2From: Effect of a rescue or recurrence dose of lasmiditan on efficacy and safety in the acute treatment of migraine: findings from the phase 3 trials (SAMURAI and SPARTAN)Outcomes at 2 h after second dose of study drug for the recurrence populationBack to article page